Publications

BibTex format

@article{Abu-Sbeih:2019:10.1200/JCO.19.01674,
author = {Abu-Sbeih, H and Faleck, D and Ricciuti, B and Mendelsohn, R and Naqash, AR and Cohen, J and Sellars, M and Balaji, A and Ben-betzalel, G and Hajir, I and Zhang, J and Awad, M and Leonardi, G and Johnson, D and Pinato, D and Owen, D and Weiss, S and Lamberti, G and Lythgoe, M and Manuzzi, L and Arnold, C and Qiao, W and Naidoo, J and Markel, G and Powell, N and Yeung, S-C and Sharon, E and Dougan, M and Wang, Y},
doi = {10.1200/JCO.19.01674},
journal = {Journal for ImmunoTherapy of Cancer},
pages = {1--12},
title = {Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease},
url = {http://dx.doi.org/10.1200/JCO.19.01674},
volume = {7},
year = {2019}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - PURPOSEThe risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI adverse events in patients with underlying IBD who received immune checkpoint inhibitors.PATIENTS AND METHODSWe performed a multicenter, retrospective study of patients with documented IBD who received immune checkpoint inhibitor therapy between January 2010 and February 2019. Backward selection and multivariate logistic regression were conducted to assess risk of GI adverse events.RESULTSOf the 102 included patients, 17 received therapy targeting cytotoxic T-lymphocyte antigen-4, and 85 received monotherapy targeting programmed cell death 1 or its ligand. Half of the patients had Crohn’s disease, and half had ulcerative colitis. The median time from last active IBD episode to immunotherapy initiation was 5 years (interquartile range, 3-12 years). Forty-three patients were not receiving treatment of IBD. GI adverse events occurred in 42 patients (41%) after a median of 62 days (interquartile range, 33-123 days), a rate higher than that among similar patients without underlying IBD who were treated at centers participating in the study (11%; P < .001). GI events among patients with IBD included grade 3 or 4 diarrhea in 21 patients (21%). Four patients experienced colonic perforation, 2 of whom required surgery. No GI adverse event–related deaths were recorded. Anti–cytotoxic T-lymphocyte antigen-4 therapy was associated with increased risk of GI adverse events on univariable but not multivariable analysis (odds ratio, 3.19; 95% CI, 1.8 to 9.48; P = .037; and odds ratio, 4.72; 95% CI, 0.95 to 23.53; P = .058, respectively).CONCLUSIONPreexisting IBD increases the risk of severe GI adverse events in patients treated with immune checkpoint inhibitors.
AU  - Abu-Sbeih,H
AU  - Faleck,D
AU  - Ricciuti,B
AU  - Mendelsohn,R
AU  - Naqash,AR
AU  - Cohen,J
AU  - Sellars,M
AU  - Balaji,A
AU  - Ben-betzalel,G
AU  - Hajir,I
AU  - Zhang,J
AU  - Awad,M
AU  - Leonardi,G
AU  - Johnson,D
AU  - Pinato,D
AU  - Owen,D
AU  - Weiss,S
AU  - Lamberti,G
AU  - Lythgoe,M
AU  - Manuzzi,L
AU  - Arnold,C
AU  - Qiao,W
AU  - Naidoo,J
AU  - Markel,G
AU  - Powell,N
AU  - Yeung,S-C
AU  - Sharon,E
AU  - Dougan,M
AU  - Wang,Y
DO  - 10.1200/JCO.19.01674
EP  - 12
PY  - 2019///
SN  - 2051-1426
SP  - 1
TI  - Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease
T2  - Journal for ImmunoTherapy of Cancer
UR  - http://dx.doi.org/10.1200/JCO.19.01674
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000496473200409&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://ascopubs.org/doi/pdf/10.1200/JCO.19.01674
UR  - http://hdl.handle.net/10044/1/75875
VL  - 7
ER  -

Download

Dr Nick Powell

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)